← Leaderboards
Phillip O Coffin
San Francisco Department Of Public Health
$23,005,135
Attributed
$25,465,025
Total exposure
18
Grants
17
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.4M · FY2011–25$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,258,822 · 15
CDC$2,206,203 · 3
By mechanism
R01$15,882,214 · 8
U01$5,187,324 · 2
K24$1,367,171 · 1
R34$1,001,898 · 2
UG3$977,129 · 1
UR6$319,604 · 1
Top collaborators
- Steven L Batki7 shared
- Jonathan D. Fuchs3 shared
- Alexander Reza Bazazi1 shared
- Vanessa Mcmahan1 shared
- John Andrew Sauceda1 shared
Others in their field
Top investigators on “Persons”
- Wafaa M. El-Sadr · Columbia University Health Sciences$688,439,560
- Lawrence Corey · Fred Hutchinson Cancer Center$646,462,796
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- David R. Weir · University Of Michigan At Ann Arbor$386,183,647
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$377,922,183
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$265,384,316
Research focus
PersonsPharmaceutical PreparationsEnrollmentSan FranciscoParticipantInterviewOpioidEventAffectEpidemicAlcohol Or Other Drugs UseProgramsBehavior TherapyVisitRandomizedDoseCounselingFundingOverdoseEnsureFutureMethamphetamineAdultBase
Grant awards (56)
Glutide for Ending Methamphetamine$977,129
UG3 · FY2025 · DA · contact PI
Behavioral Safety and Fentanyl Education: BSAFE$620,164
R01 · FY2025 · DA · contact PI
Midcareer K24 Award for Mentoring and Patient-Oriented Research$199,597
K24 · FY2025 · DA · contact PI
PRIME: PrEP Intervention for people who Inject MEthamphetamine$738,862
R01 · FY2024 · DA · contact PI
Midcareer K24 Award for Mentoring and Patient-Oriented Research$200,393
K24 · FY2024 · DA · contact PI
PRIME: PrEP Intervention for people who Inject MEthamphetamine$828,852
R01 · FY2023 · DA · contact PI
Leveraging Psychological Autopsies to Accelerate Research into Stimulant Overdose Mortality$362,432
R01 · FY2023 · CE · contact PI
Midcareer K24 Award for Mentoring and Patient-Oriented Research$202,510
K24 · FY2023 · DA · contact PI
PRIME: PrEP Intervention for people who Inject MEthamphetamine$828,852
R01 · FY2022 · DA · contact PI
Repeated-dose behavioral intervention to reduce opioid overdose: a two-site randomized-controlled efficacy trial$692,881
R01 · FY2022 · DA · contact PI
Leveraging Psychological Autopsies to Accelerate Research into Stimulant Overdose Mortality$362,432
R01 · FY2022 · CE · contact PI
Mirtazapine for methamphetamine use disorder: drug-drug interaction study$2,182,386
U01 · FY2021 · DA · contact PI
Repeated-dose behavioral intervention to reduce opioid overdose: a two-site randomized-controlled efficacy trial$831,492
R01 · FY2021 · DA · contact PI
PRIME: PrEP Intervention for people who Inject MEthamphetamine$828,852
R01 · FY2021 · DA · contact PI
Leveraging Psychological Autopsies to Accelerate Research into Stimulant Overdose Mortality$362,384
R01 · FY2021 · CE · contact PI
Mirtazapine for methamphetamine use disorder: drug-drug interaction study$2,205,587
U01 · FY2020 · DA · contact PI
Repeated-dose behavioral intervention to reduce opioid overdose: a two-site randomized-controlled efficacy trial$831,618
R01 · FY2020 · DA · contact PI
PRIME: PrEP Intervention for people who Inject MEthamphetamine$786,761
R01 · FY2020 · DA · contact PI
Cohort Study of Opioids, Pain, and Safety in an era of Changing Policy (COPING)$394,363
R01 · FY2020 · DA · contact PI
Mid-Career Award in Patient-Oriented Substance Use Research Addressing Opioids, Chronic Pain, and HIV$151,319
K24 · FY2020 · DA · contact PI
Repeated-dose behavioral intervention to reduce opioid overdose: a two-site randomized-controlled efficacy trial$811,238
R01 · FY2019 · DA · contact PI
Cohort Study of Opioids, Pain, and Safety in an era of Changing Policy (COPING)$439,218
R01 · FY2019 · DA · contact PI
REBOOT Admin Supplement$158,402
R01 · FY2019 · DA · contact PI
Mid-Career Award in Patient-Oriented Substance Use Research Addressing Opioids, Chronic Pain, and HIV$151,319
K24 · FY2019 · DA · contact PI
SHARP: Summer HIV/AIDS Research Program$104,519
R25 · FY2019 · DA
Repeated-dose behavioral intervention to reduce opioid overdose: a two-site randomized-controlled efficacy trial$716,100
R01 · FY2018 · DA · contact PI
Cohort Study of Opioids, Pain, and Safety in an era of Changing Policy (COPING)$445,565
R01 · FY2018 · DA · contact PI
Mid-Career Award in Patient-Oriented Substance Use Research Addressing Opioids, Chronic Pain, and HIV$151,319
K24 · FY2018 · DA · contact PI
SHARP: Summer HIV/AIDS Research Program$104,519
R25 · FY2018 · DA
Cohort Study of Opioids, Pain, and Safety in an era of Changing Policy (COPING)$454,560
R01 · FY2017 · DA · contact PI
Mirtazapine for the treatment of methamphetamine dependence among MSM with high-r$406,960
R01 · FY2017 · DA · contact PI
Substance use outcomes of opioid dose reduction and discontinuation$399,558
U01 · FY2017 · CE · contact PI
Mid-Career Award in Patient-Oriented Substance Use Research Addressing Opioids, Chronic Pain, and HIV$153,479
K24 · FY2017 · DA · contact PI
Hepatitis C Treatment As Prevention Pilot Study with Ledipasvir-Sofosbuvir Among People Actively Injecting Drugs (TasP-C Pilot)$114,015
R34 · FY2017 · DA · contact PI
SHARP: Summer HIV/AIDS Research Program$108,000
R25 · FY2017 · DA
Cohort Study of Opioids, Pain, and Safety in an era of Changing Policy (COPING)$479,385
R01 · FY2016 · DA · contact PI
Mirtazapine for the treatment of methamphetamine dependence among MSM with high-r$467,860
R01 · FY2016 · DA · contact PI
Substance use outcomes of opioid dose reduction and discontinuation$399,793
U01 · FY2016 · CE · contact PI
Naltrexone for the treatment of Actively-Using Met-Dependent MSM with High-Risk B$228,809
R01 · FY2016 · DA · contact PI
Hepatitis C Treatment As Prevention Pilot Study with Ledipasvir-Sofosbuvir Among People Actively Injecting Drugs (TasP-C Pilot)$193,031
R34 · FY2016 · DA · contact PI
Mid-Career Award in Patient-Oriented Substance Use Research Addressing Opioids, Chronic Pain, and HIV$157,235
K24 · FY2016 · DA · contact PI
Repeated-dose Brief Intervention to Reduce Overdose and Risk Behaviors Among Nalo$137,587
R34 · FY2016 · DA · contact PI
Naltrexone for the treatment of Actively-Using Met-Dependent MSM with High-Risk B$524,718
R01 · FY2015 · DA · contact PI
Mirtazapine for the treatment of methamphetamine dependence among MSM with high-r$466,296
R01 · FY2015 · DA · contact PI
Repeated-dose Brief Intervention to Reduce Overdose and Risk Behaviors Among Nalo$197,384
R34 · FY2015 · DA · contact PI
Hepatitis C Treatment As Prevention Pilot Study with Ledipasvir-Sofosbuvir Among People Actively Injecting Drugs (TasP-C Pilot)$193,453
R34 · FY2015 · DA · contact PI
An Assessment of Opioid Overdoses in San Francisco from 2010 through 2012$54,076
R03 · FY2015 · DA · contact PI
Naltrexone for the treatment of Actively-Using Met-Dependent MSM with High-Risk B$550,847
R01 · FY2014 · DA · contact PI
Mirtazapine for the treatment of methamphetamine dependence among MSM with high-r$473,397
R01 · FY2014 · DA · contact PI
Repeated-dose Brief Intervention to Reduce Overdose and Risk Behaviors Among Nalo$166,428
R34 · FY2014 · DA · contact PI
Naloxone prescription for Opioid Safety Evaluation (NOSE)$166,421
R21 · FY2014 · DA · contact PI
An Assessment of Opioid Overdoses in San Francisco from 2010 through 2012$54,900
R03 · FY2014 · DA · contact PI
Mirtazapine for the treatment of methamphetamine dependence among MSM with high-r$476,548
R01 · FY2013 · DA · contact PI
Naloxone prescription for Opioid Safety Evaluation (NOSE)$137,250
R21 · FY2013 · DA · contact PI
Reducing HIV risk among episodic substance-using MSM$319,604
UR6 · FY2011 · PS · contact PI
Aripiprazole to reduce methamphetamine use among MSM with high-risk HIV behaviors$312,366
R01 · FY2011 · DA · contact PI